- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06702592
Виртуальная поддержка рака яичка и цель выживания 2 (VITALSS)
Виртуальная поддержка и выживание больных раком яичка (исследование VITALSS), цель 2
This study examines how virtual support can enhance well-being and survivorship in men with testicular cancer. Participants in North Carolina will be randomized into two groups: one with access to a virtual support platform and the other with access to patient educational materials only. After six months, the emotional well-being, self-efficacy, financial toxicity, and quality of life of both groups will be compared at 3 months and 6 months after baseline assessments.
Обзор исследования
Статус
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Deborah S Usinger
- Номер телефона: 919-962-5431
- Электронная почта: dusinger@email.unc.edu
Учебное резервное копирование контактов
- Имя: Taylor J Greene
- Номер телефона: 919-962-5506
- Электронная почта: taylor_greene@med.unc.edu
Места учебы
-
-
North Carolina
-
Chapel Hill, North Carolina, Соединенные Штаты, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Главный следователь:
- Hung-Jui Tan, MD, MSHPM
-
Контакт:
- Deborah M Usinger
- Номер телефона: 919-962-0000
- Электронная почта: dusinger@email.unc.edu
-
Контакт:
- Taylor L Greene
- Номер телефона: (919) 962-0000
- Электронная почта: taylor_greene@med.unc.edu
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Men within 5 years of their initial diagnosis of germ cell testicular cancer.
- The subject is willing and able to comply with study procedures based on the judgment of the investigator.
- Adults aged 18-95 years old.
- Electronic informed consent was obtained to participate in the study.
Exclusion Criteria:
- Woman gender
- Non-English speaking
- Unwilling or unable to complete informed consent.
- On active treatment for another cancer.
- Actively receiving chemotherapy, radiation, or surgery for testicular cancer.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Исследования в области здравоохранения
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Virtual support
Participants will have access to the virtual support platform. |
Subjects will use a virtual support platform that was built for their needs. |
|
Другой: Patient educational material
Participants will have access to patient educational material only. |
Participants will have access to patient educational material. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Emotional well-being scores comparison
Временное ограничение: At baseline, 3-months, and 6-months
|
Emotional well-being will be assessed by patient-reported outcomes questionnaires using a 9-item Positive Affect and Well-Being assessment from the Neuro-QOL Item Bank v1. Emotional well-being scores in virtual support and enhanced usual care will be compared. It is a 5-point Likert scale, higher scores reflect better emotional well-being. |
At baseline, 3-months, and 6-months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Negative mental health comparison
Временное ограничение: At baseline, 3-months, and 6-months
|
Negative mental health will be assessed by patient-reported outcomes questionnaires using 17 PROMIS items for anxiety, depression, loneliness, and stress. Negative mental health scores in virtual support and enhanced usual care will be compared. Scoring: Each item is rated on a 5-point scale between never (1) to always (5). The responses for each item are summed to get a total raw score. T-Scores: The raw score is then converted to a T-score using a scoring table specific to the PROMIS Anxiety item bank. T-scores standardize the results, making them comparable across different populations and studies. A T-score has a mean of 50 and a standard deviation of 10 in the general population. |
At baseline, 3-months, and 6-months
|
|
Social well-being, acceptance and inclusion comparison
Временное ограничение: At baseline, 3-months, and 6-months
|
Social well-being will be assessed by patient-reported outcomes questionnaires using the 6-item Acceptance/Inclusion subscale of the General Belongingness Scale (GBS). GBS measures an individual's sense of belonging and social connectedness. It consists of 12 items that assess feelings of acceptance and inclusion. Each item is rated on a 7-point Likert scale (1 = Strongly Disagree and 7 = Strongly Agree). Higher scores reflect better inclusion. Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
Financial Toxicity comparison
Временное ограничение: At baseline, 3-months, and 6-months
|
Financial Toxicity will be assessed by patient-reported outcomes questionnaires using a 12-item Comprehensive Score for Financial Toxicity (COST) instrument. Each item is rated on a 5-point Likert scale 0= = Not at all to 4= Very much. Higher scores indicate higher financial difficulties. Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
Self-efficacy comparison
Временное ограничение: At baseline, 3-months, and 6-months
|
Self-efficacy will be assessed by patient-reported outcomes questionnaires using 20 PROMIS items for self-efficacy for managing daily activities, emotions, social interactions, and symptoms. Self-efficacy scores in virtual support and enhanced usual care will be compared. Each item is rated on a 5-point scale ( 1 = Never, 5 = Always). Responses are summed to get a total raw score for each domain. Raw scores are converted to T-scores using a scoring table. T-scores standardize results, with a mean of 50 and a standard deviation of 10 in the general population. |
At baseline, 3-months, and 6-months
|
|
Sexual Function and Satisfaction comparison
Временное ограничение: At baseline, 3-months, and 6-months
|
Sexual Function and Satisfaction will be assessed by patient-reported outcomes questionnaires using a 20-item PROMIS SexFS instrument with domains for interest in sexual activity, global satisfaction with sex life, orgasm, and erectile function. Scores in virtual support and enhanced usual care will be compared. Each item is rated on a 5-point Likert scale: 1 = Not at all to 5= Very much. Raw scores are converted to T-scores using a scoring table specific to the PROMIS Sexual Function and Satisfaction profile. T-scores standardize the results, with a mean of 50 and a standard deviation of 10 in the general population.Higher T-scores indicate better sexual function and satisfaction. |
At baseline, 3-months, and 6-months
|
|
Functional well-being comparison Functional well-being comparison
Временное ограничение: At baseline, 3-months, and 6-months
|
Functional well-being will be assessed by patient-reported outcomes questionnaires using a 7-item subscale of the Functional Assessment of Cancer Therapy (FACT-G) instrument. Each item is rated on a 5-point Likert scale, 0= = Not at all to 4= Very much. Higher scores indicate better well-being. Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
General Quality of Life comparison
Временное ограничение: At baseline, 3-months, and 6-months
|
General Quality of Life will be assessed by patient-reported outcomes questionnaires using the PROMIS Global Health scale is an 8-item, validated survey that represents five core domains (physical function, pain, fatigue, emotional distress, social health). Two items each for physical and mental health as well as a question on quality of life will be administered. Scores in virtual support and enhanced usual care will be compared. Each item is rated on a 5-point Likert scale:1 = Poor to 5 = Excellent. Responses are summed to get a total raw score. The raw score is converted to a T-score using a scoring table. T-scores standardize the results, with a mean of 50 and a standard deviation of 10 in the general population. Higher T-scores indicate better overall health |
At baseline, 3-months, and 6-months
|
|
General Self-Efficacy comparison
Временное ограничение: At baseline, 3-months, and 6-months
|
General Self-Efficacy will be assessed by patient-reported outcomes questionnaires using the 4-item PROMIS instrument that measures the respondent's belief in managing specific problems or issues. Each item is scored on a 5-point Likert scale, 1 = Never to 5 = Always. The raw score is then converted to a T-score using a scoring table specific to the PROMIS domain being measured. T-scores standardize the results, with a mean of 50 and a standard deviation of 10 in the general population. Higher T-scores indicate more of the concept being measured Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
Virtual platform usage
Временное ограничение: At baseline, 3-months, and 6-months
|
Virtual platform usage will be assessed by time, visits, scrolling, posts, and messages spent on the virtual platform. |
At baseline, 3-months, and 6-months
|
|
Healthcare and supportive care utilization
Временное ограничение: At baseline, 3-months, and 6-months
|
Self-reported use of healthcare and supportive care services will be assessed by a survey. Participants will be asked to quantify healthcare or other supportive care visits over the intervention period. |
At baseline, 3-months, and 6-months
|
Соавторы и исследователи
Соавторы
Следователи
- Главный следователь: Hung-Jui Tan, MD, UNC Lineberger Comprehensive Cancer Center
Публикации и полезные ссылки
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Генитальные заболевания
- Заболевания эндокринной системы
- Генитальные новообразования, мужчины
- Урогенитальные новообразования
- Новообразования по локализации
- Новообразования
- Заболевания половых органов, мужчины
- Мужские мочеполовые заболевания
- Поведенческие симптомы
- Новообразования эндокринных желез
- Заболевания гонад
- Стресс, Психологический
- Заболевания яичек
- Поведение
- Финансовый стресс
- Новообразования яичка
Другие идентификационные номера исследования
- LCCC2418 AIM2
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .